ADVFN - Advanced Financial Network.
HOME» NASDAQ » A » ACOR Stock Price » ACOR Stock News

Acorda Therapeutics Share News

 Acorda Therapeutics (mm) Stock Price
ACOR Stock Price
 Acorda Therapeutics (mm) Stock Chart
ACOR Stock Chart
 Acorda Therapeutics (mm) Stock News
ACOR Stock News
 Acorda Therapeutics (mm) Company Information
ACOR Company Information
 Acorda Therapeutics (mm) Stock Trades
ACOR Stock Trades

Biogen Gets Letter Of Deficiency From Health Canada On Fampridine

By Thomas Gryta Of DOW JONES NEWSWIRES NEW YORK -(Dow Jones)- Biogen Idec Inc. (BIIB) has received a letter of deficiency from Health Canada for its application to sell the multiple sclerosis treatment fampridine in the country. The Weston, Mass., biotech company also recently received questions from the European Medicines Agency on an application to sell the same drug in the region. Biogen expects a decision later this month. The disclosures were made at the JPMorgan healthcare conference in San Francisco Tuesday by Chief Executive George Scangos. Scangos declined to comment on the letter or provide any further detail about the questions from the regulators. Fampridine helps improve walking in multiple sclerosis patients and is sold in the U.S. by Acorda Therapeutics Inc. (ACOR) under the name Ampyra. Separately, the company said that about 56,000 patients are using its MS drug Tysabri as of the end of December, an increase of 1,700 patients from fourth quarter and down from the 2,100 patients added in the third quarter. -By Thomas Gryta, Dow Jones Newswires; 212-416-2169;

Stock News for Acorda Therapeutics (ACOR)
05/15/201517:39:40Statement of Changes in Beneficial Ownership (4)
05/08/201517:25:03Quarterly Report (10-q)
05/05/201507:00:00Acorda Therapeutics to Present at the Bank of America Merrill...
05/01/201507:00:00Acorda Therapeutics to Present at the Deutsche Bank 40th Annual...
05/01/201503:37:14Canaccord Genuity Reaffirms Hold Rating for Acorda Therapeutics...
05/01/201503:14:17Acorda Therapeutics Receives Neutral Rating from JPMorgan Chase...
04/30/201506:51:30Current Report Filing (8-k)
04/30/201506:00:00Acorda Reports First Quarter 2015 Financial Results
04/23/201507:00:00Acorda Therapeutics to Host Conference Call to Discuss First...
04/22/201507:56:12Current Report Filing (8-k)
04/22/201507:30:00Acorda Presents Data on First Clinical Study of Remyelinating...
04/22/201507:01:00Acorda Therapeutics Named One of the Best Places to Work For...
04/22/201504:49:35Acorda Therapeutics Research Coverage Started at Piper Jaffray...
04/19/201514:07:03This New Hedge Fund Strategy Just Might Be Crazy Enough To Work
04/19/201513:01:02Will This Hedge Fund Manager Bring Down Your Biotech Stocks?
04/08/201512:55:14Confidential Treatment Order (ct Order)
04/07/201519:51:27Kyle Bass's New Tack: Dispute the Patent, Short the Stock
04/07/201516:49:59Hedge-Fund Manager Challenges Jazz Pharmaceuticals Patent
03/18/201506:02:49Not In Favor Of The Solar Industry - Cramer's Lightning Round...
03/16/201512:13:00Acorda Rings NASDAQ Opening Bell to Mark 20th Anniversary

Acorda Therapeutics and other NASDAQ stock quotes are delayed by at least 20 minutes.
All other stock price and quote data is delayed by at least 15 minutes unless otherwise stated. By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2007 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations